News - Novartis

Filter

Current filters:

Novartis

Popular Filters

376 to 386 of 386 results

Sandoz files for generic of Shire’s Vyvanse; FDA warning

20-05-2011

Ireland-headquartered biopharmaceutical company Shire (LSE: SHP) yesterday revealed that its US subsidiary…

GenericsMarkets & MarketingNeurologicalNorth AmericaNovartisPatentsPharmaceuticalRegulationSandozShireVyvanse

Novartis’ Votubia cleared as first drug in Switzerland for SEGA

11-05-2011

Swissmedic, the Swiss drug regulation agency, has approved domestic drug major Novartis’ (NOVN:…

EuropeeverolimusNovartisOncologyPharmaceuticalRare diseasesRegulationVotubia

UK’s NICE says “no” to Novartis Tasigna and B-MS Sprycel, but better news on Afinitor

06-05-2011

The UK’s drug rationing body the National Institute for Health and Clinical Excellence (NICE) yesterday…

AfinitorBristol-Myers SquibbGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

New study reveals risks with Roche’s Avastin for wet AMD versus Lucentis

05-05-2011

A new Medicare analysis conducted by Johns Hopkins University in the USA was presented yesterday at the…

AvastinLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

Novartis gains EU approval for combo drug Rasilamlo to treat high BP

29-04-2011

Swiss drug major Novartis (NOVN: VX) says that Rasilamlo, a single-pill combination of aliskiren and…

Cardio-vascularEuropeNovartisPharmaceuticalRasilamloRegulation

Vaccine to halt Alzheimer's could be available within few years

26-04-2011

A vaccine that has the potential to stop Alzheimer's disease progression could be available within a…

BiotechnologyCytos BiotechnologyNeurologicalNovartisPharmaceuticalResearchVaccines

Novartis withdraws MA for Joicela; gets “no” from UK's NICE for Afinitor

20-04-2011

There were two pieces of negative news for Swiss drug major Novartis (NOVN: VX) yesterday, when the company…

AfinitorEuropeJoicelalumiracoxibNeurologicalNovartisOncologyPharmaceuticalRegulation

Novartis 1st-qtr 2011 hit by strong franc but still beats forecasts

19-04-2011

Swiss drug major Novartis (NOVN: VX) reported a 16% rise (+14% at constant currencies) in first-quarter…

AlconFinancialNovartisPharmaceuticalSandoz

78% of US health plans will reimburse for emerging oral therapies for multiple sclerosis, study suggests

18-04-2011

A large percentage of US health plans (78%) will reimburse for emerging oral disease-modifying therapies…

GilenyaNeurologicalNorth AmericaNovartisPharmaceuticalPricing

376 to 386 of 386 results

Company Spotlight

Fibrotech

Fibrotech

Back to top